DesiRTA: A Targeted Nanotherapeutic Approach for Revolutionizing Arthritis Treatment
Arthritis, a prevalent global health concern affecting over 350 million individuals, substantially burdens healthcare systems. This chronic condition, characterized by joint pain, edema, and restricted mobility, significantly impairs patients' quality of life and contributes considerably to work disability. Current therapeutic interventions, including non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and disease-modifying antirheumatic drugs (DMARDs), often yield suboptimal efficacy and are associated with undesirable side effects, such as osteoporosis and hyperglycemia. Consequently, there is an urgent clinical need for safer, more effective, and targeted treatment modalities.
DesiRTA (Localized and Controlled co-delivery of AuNPs conjugated siRNA by Cationic Shear-thinning Gel Matrix for Treatment of Arthritis) endeavors to address this unmet need by developing a novel therapeutic strategy employing gold nanoparticles (AuNPs) and small interfering RNA (siRNA). siRNA demonstrates significant therapeutic promise by selectively silencing genes implicated in arthritis progression. However, its clinical translation is limited by challenges such as enzymatic degradation and suboptimal cellular internalization. DesiRTA overcomes these limitations by conjugating siRNA with AuNPs. These AuNPs protect against degradation and enhance cellular uptake and exhibit inherent anti-inflammatory properties. The resulting AuNP-siRNA conjugates are further stabilized and delivered via an innovative shear-thinning hydrogel. This biocompatible hydrogel, engineered to mimic synovial fluid, facilitates facile injection and enables sustained release of the therapeutic payload directly into the affected joint.
The DesiRTA project follows a structured pathway to impact, encompassing several key stages. Initially, a library of stable AuNP-siRNA biopolymer complexes will be generated. Subsequently, the shear-thinning injectable hydrogel carrier will be synthesized. Finally, the formulation's release kinetics, stability, and in-vitro and in-vivo performance will be rigorously assessed. DesiRTA's innovative approach offers several potential breakthroughs: the development of ultra-stable AuNP-siRNA conjugates for sustained and controlled delivery, a tailored shear-thinning hydrogel matrix for localized treatment, and the synergistic action of AuNPs and siRNA to simultaneously modulate multiple disease-modifying factors. By mitigating in-vivo siRNA degradation and enabling targeted gene silencing, DesiRTA can potentially transform arthritis therapy.
